REG - Faron Pharma. Oy - Faron Announces R&D Day

Faron Pharmaceuticals OyAnnouncement

14/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220214:nRSN5089Ba&default-theme=true

RNS Number : 5089B  Faron Pharmaceuticals Oy  14 February 2022

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Faron announces R&D Day to be held on February 23, 2022

 

Company announcement, February 14, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) /
02:00 AM (EDT)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, today announces plans to host a virtual
R&D Day via webcast on Wednesday, February 23 at 4:00 pm EET, 2:00 pm GMT,
9:00 am EDT.

 

Dr. Markku Jalkanen, Chief Executive Officer, will host the event together
with members of the Faron Global Management Team. In addition, the following
external experts will provide additional perspectives:

 

·      Dr. Tyler Curiel, Professor of Medicine and Microbiology,
Immunology & Molecular Genetics at The University of Texas Health Science
Center at San Antonio, United States

·      Dr. Maija Hollmén, Adjunct Professor of Tumour Immunology, Group
Leader and Academy Research Fellow at the MediCity Research Laboratory,
Institute of Biomedicine, University of Turku, Finland

 

As part of the event, Faron's new Chief Medical Officer, Dr. Marie-Louise
Fjällskog, will provide an update on bexmarilimab, the Company's wholly-owned
novel precision cancer immunotherapy in Phase I/II development, targeting
Clever-1, a receptor known to be expressed on immunosuppressive macrophages in
the tumor microenvironment. Dr. Fjällskog will share updated survival data
from the ongoing MATINS trial and provide an overview of the accelerated
bexmarilimab development plan, including a review of the latest biomarker
analysis and strategy. There will be an opportunity to ask questions during
the webcast.

 

"I am delighted to be hosting this R&D Day with our invited speakers who
will provide important insights into the immunotherapy approaches currently
available to patients and work Faron is doing to potentially bring the promise
of immunotherapy to a broader patient group," said Dr. Markku Jalkanen, Chief
Executive Officer of Faron.  "The unfortunate reality is that currently, only
a small segment of cancer patients benefit from immunotherapy and there
remains an urgent clinical need to identify new treatment approaches."

 

To register for Faron's R&D Day on February 23, 2022, please visit:
https://faron.videosync.fi/r-and-d-day
(https://faron.videosync.fi/r-and-d-day) .

 

A Finnish language interview with Dr. Markku Jalkanen covering the important
information shared during the R&D Day event will also take place on
February 23, 2022. A link to a recording of this interview will be made
available on the "Investors" section on Faron's website at:
 https://www.faron.com/investors (https://www.faron.com/investors) .

 

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com (mailto:Eric.vanzanten@faron.com)

Investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Investor Contact

Stern Investor Relations

Julie Seidel

julie.seidel@sternir.com (mailto:Julie.seidel@sternir.com)

Phone: +1 (212) 362-1200

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

 

About Bexmarilimab

Bexmarilimab is Faron's wholly-owned, investigative precision immunotherapy
with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid cell function. A novel
anti-Clever-1 humanised antibody, bexmarilimab targets Clever-1 positive
(Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumour
associated macrophages (TAMs) in the tumour microenvironment, converting these
highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages.
In mouse models, bexmarilimab has successfully blocked or silenced Clever-1,
activating antigen presentation and promoting interferon gamma secretion by
leukocytes. Additional pre-clinical studies have proven that Clever-1, encoded
by the Stabilin-1 or STAB-1 gene, is a major source of T cell exhaustion and
involved in cancer growth and spread. Observations from clinical studies to
date indicate that Clever-1 has the capacity to control T cell activation
directly, suggesting that the inactivation of Clever-1 as an immune
suppressive molecule could be more broadly applicable and more important than
previously thought. As an immuno-oncology therapy, bexmarilimab has potential
as a single-agent therapy or in combination with other standard treatments
including immune checkpoint molecules. Beyond immuno-oncology, it offers
potential in infectious diseases, vaccine development and more.

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function. Currently in
Phase I/II clinical development as a potential therapy for patients with
untreatable solid tumors, bexmarilimab has potential as a single-agent therapy
or in combination with other standard treatments including immune checkpoint
molecules. Traumakine is an investigational intravenous (IV) interferon
beta-1a therapy for the treatment of acute respiratory distress syndrome
(ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is
currently being evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing of the US
Air Force and the US Department of Defense for the prevention of multiple
organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by
a major trauma.  Faron is based in Turku, Finland. Further information is
available at www.faron.com (http://www.faron.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTJMPTMTABBRT